Physician profile
Mary E Clinton
NPI 1760484760
$1,651.94
in general payments reported to CMS, 2019-2025
29 companies · $741 in 2025
The $741 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $120 · 2021: $189 · 2022: $18.85 · 2023: $186 · 2024: $256 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.31 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $206.51 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Sk Life Science, INC. | $116.47 | 2021-2025 | |
| Pfizer INC. | $109.03 | 2023-2025 | |
| Ucb, INC. | $99.02 | 2025 | Briviact, Fintepla |
| Abbvie INC. | $91.37 | 2021-2025 | |
| Tg Therapeutics, INC. | $89.19 | 2025 | |
| Novartis Pharmaceuticals Corporation | $84.63 | 2020-2025 | |
| Genzyme Corporation | $73.39 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $68.51 | 2025 | |
| Emd Serono, INC. | $66.62 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $61.75 | 2021-2023 | Ultomiris |
| Celgene Corporation | $60.77 | 2021-2025 | Zeposia |
| Amgen INC. | $55.62 | 2019-2024 | Uplizna |
| Allergan, INC. | $51.20 | 2020 | |
| Acadia Pharmaceuticals INC | $47.24 | 2025 | Nuplazid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $47.10 | 2023 | Uplizna |
| Biogen, INC. | $44.83 | 2019 | |
| Lundbeck LLC | $36.33 | 2019-2025 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $35.76 | 2025 | |
| Neurelis, INC. | $35.64 | 2024-2025 | Valtoco |
| W. L. Gore & Associates, INC. | $24.18 | 2025 | Gore Cardioform Septal Occluder |
| Janssen Pharmaceuticals, INC | $22.80 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.96 | 2021 | |
| Medtronic, INC. | $20.94 | 2024 | Percept PC Brainsense |
| E.R. Squibb & Sons, L.L.C. | $19.77 | 2020 | |
| Greenwich Biosciences, INC. | $19.18 | 2021 | |
| Eisai INC. | $16.51 | 2024 | |
| Cycle Pharmaceuticals INC | $14.03 | 2025 | Tascenso Odt, Bafiertam |
| Zyla Life Sciences, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Clinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.